A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient ...

GLP-1 RAs may have an anti-inflammatory benefit, suggesting potential use in other ocular inflammatory diseases. Patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have roughly ...

Amid the surge in GLP-1 weight-loss medications, some have questioned whether invasive procedures like lap band, gastric sleeve and bypass surgeries could wane in popularity. Carnie Wilson, of the ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and ...

SEATTLE — A medication originally designed to treat diabetes is showing unexpected promise in fighting addiction. Medications like Ozempic, already popular for weight loss, may help reduce cravings ...

Introduction Idiopathic intracranial hypertension (IIH) is characterized by elevated intracranial pressure and most commonly affects obese women. While its etiology remains unclear, many patients ...